Biotech
-
Takeda to stop making parathyroid drug Natpara in 2024 after production challenges
The Japanese drugmaker said it was unable to resolve manufacturing problems that led to a 2019 recall of the drug,…
Read More » -
Pfizer says PARP inhibitor succeeds in prostate cancer study
AstraZeneca paved the way for PARPs in prostate cancer when it won an approval for Lynparza in advanced patients. Now…
Read More » -
KalVista stops work on rare disease drug over safety concerns
The biotech terminated a Phase 2 study after treatment led to serious liver enzyme elevations in multiple patients with hereditary…
Read More » -
Former Spark CEO Marrazzo joins epigenetics startupâs board
Chroma Medicine, which launched last year with $125 million in funding, has drawn several high-profile biotech leaders to it, including…
Read More » -
A Flagship startup secures $121M in new funding
Cellarity is the second Flagship company in as many months to raise a Series C round instead of filing to…
Read More » -
Incyte, branching out in dermatology, to buy startup Villaris
The acquisition, Incyte’s first of an entire company, hands the pharmaceutical company a potentially long lasting treatment for the skin…
Read More » -
Myovant rejects $2.4B buyout offer from Japanese majority owner
The biotech said the proposed offer “significantly undervalues” the company, but that it’s open to considering a higher bid.
Read More » -
AstraZeneca to acquire gene editing biotech LogicBio
Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of…
Read More » -
Biogen, Denali begin late-stage testing of Parkinsonâs drug
Part of a $1 billion alliance the companies formed in 2020, the drug will be tested in a large study of patients…
Read More » -
5 FDA decisions to watch in the fourth quarter
The regulator could soon approve medicines from Apellis, Gilead and GSK, and decide whether to pull a controversial preterm birth drug…
Read More »